Veru Stock: Saving Muscle Mass Amidst The GLP-1 Drug Boom (NASDAQ:VERU)

Veru Stock: Saving Muscle Mass Amidst The GLP-1 Drug Boom (NASDAQ:VERU)

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield peak sales in billions. See more on VERU.

GLP-1R Agonists: Pioneering in Metabolic, Neurologic, and Cardiologic Markets

DUBLIN--(BUSINESS WIRE)--May 26, 2025-

GLP-1 Drug Use Surges 600% as 2% of Americans Take Weight-Loss Medications

An anonymous reader shares a report: More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given to Axios first. The data from FAIR Health's repository of over 51 billion commercial h...

GLP-1R Agonists: Pioneering in Metabolic, Neurologic, and Cardiologic Markets - ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “GLP-1R Agonists – Label Extensions/Drug Repurposing: Market Overview” report has been added to ResearchAndMarkets.com’s offering. This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity. The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties. GLP-1RAs are being invest…